Garadacimab is a medicine that helps prevent swelling attacks in people with hereditary angioedema (HAE). It is a shot given under the skin. It works by blocking a protein that starts the chain reaction behind the swelling.
Every report comes from a Lived member, sent anonymously.
Have you tried Andembry (Garadacimab) for Hereditary Angioedema?
Garadacimab, sold as Andembry, is a prescription medicine taken to prevent attacks of hereditary angioedema (HAE) in adults and children aged 12 and older. HAE is a rare inherited condition that causes repeated episodes of deep, painful swelling, most often in the hands, feet, face, gut and throat. Attacks in the gut can cause severe abdominal pain and vomiting, and swelling in the throat can block breathing. Andembry is a preventive treatment, also called long-term prophylaxis: it is taken on a regular schedule to make attacks much less frequent. It does not stop an attack that has already started, so people using it still need a separate on-demand medicine for attacks. Approved in the US in 2025, it is one of several first-line preventive options, alongside lanadelumab (Takhzyro), berotralstat (Orladeyo) and C1 inhibitor replacement. Its main study enrolled people with the two most common types of HAE, in which a protein called C1 inhibitor is either too low or does not work properly.
The swelling in HAE is driven by bradykinin, a small protein fragment that makes blood vessels leak fluid into the surrounding tissue. Normally, C1 inhibitor keeps bradykinin production in check. When an inherited gene change leaves too little working C1 inhibitor, the chain reaction that makes bradykinin can run unchecked and set off an attack. Garadacimab is a monoclonal antibody, a lab-made protein designed to attach to one specific target. Its target is activated factor XII, the enzyme at the very start of that chain reaction. By blocking this first step, garadacimab reduces how much bradykinin is produced, which lowers the chance that swelling begins. Other preventive medicines work at later steps of the same chain or replace the missing C1 inhibitor.
Andembry is injected under the skin from a single-dose prefilled autoinjector or prefilled syringe. Treatment starts with a loading dose of two injections on the first day, followed by one injection once a month. After training from the care team, most people inject at home themselves, or a caregiver gives the dose. The thigh or belly is used, staying about an inch away from the navel; the upper arm can be used when someone else gives the injection. Adolescents should inject under an adult's supervision. The pens and syringes are kept in the refrigerator in their carton, never frozen or shaken, and are left out for about 30 minutes to reach room temperature before injecting. If a dose is missed, give it as soon as possible. Used devices go into a sharps container.
In the main six-month study, the side effects that were more common with Andembry than with placebo were cold-like symptoms (a runny or stuffy nose, sneezing or watery eyes) and stomach pain. Reactions where the shot was given, such as redness, itching, bruising or a small raised welt, occurred in about 1 in 7 people across the studies and were generally mild. In pooled data from people treated for up to about five years, no serious side effects were judged to be caused by the medicine, although total experience is still limited because HAE is rare. Mention any side effect that is bothersome or does not go away. Because stomach pain is also a common sign of an HAE attack in the gut, it is worth asking the care team how to tell the two apart.
The label lists no contraindications (situations in which the medicine must not be used) and no specific warnings, and no formal drug interaction studies have been done. Its main practical interaction is with a blood test. Factor XII also plays a part in a common clotting test called the aPTT (activated partial thromboplastin time), so Andembry can make that result look longer, as if blood were clotting more slowly. Some people in the study also had higher results on two other clotting measurements, the PT (prothrombin time) and INR (international normalized ratio). None of these changes came with bleeding, but they can be misread, so tell any doctor, surgeon or lab ordering clotting tests that you take Andembry. There are no human data on Andembry during pregnancy or breastfeeding. Antibody medicines like this one cross the placenta mainly late in pregnancy, so anyone pregnant, planning a pregnancy or breastfeeding should weigh the options with their HAE specialist. Andembry has not been studied in children under 12. Andembry lowers the risk of attacks but does not remove it, so keep on-demand attack medicine with you at all times; guidelines recommend having enough for at least two attacks. Swelling of the throat or tongue, a lump feeling in the throat, hoarseness, trouble swallowing or difficult or noisy breathing can mean the airway is closing: use your on-demand medicine right away and get emergency medical care, even if the medicine seems to be helping.
In the main study, people taking Andembry had about 89% fewer attacks per month than people taking placebo over six months, and about 6 in 10 had no attacks at all during that time, compared with none on placebo. Protection tends to begin early, and in longer follow-up of up to about three years the reduction in attacks held steady. Responses vary, and some people still have occasional attacks; keeping a record of them helps the care team judge how well the treatment is working. HAE is lifelong, and Andembry is intended as ongoing treatment rather than a short course. The monthly schedule means far fewer injections than some older preventive options that are given up to twice a week, which can make treatment easier to fit into daily life. Before dental work, surgery or other procedures, especially those involving the mouth or throat, ask whether extra short-term protection is needed even while on Andembry.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Andembry (Garadacimab), what you've noticed, or ask the community a question.